AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02218489
Drug: KPI-121
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
Trial: NCT01157377
Drug: AGN-214868
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-214868 injected into the bladder.
Trial: NCT01157377
Drug: AGN-214868 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-214868 placebo injected into the bladder.
Trial: NCT00118703
Drug: GW685698X
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01759238
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825mg/m2 per os bid
Trial: NCT04211272
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin will be administrated as film-coated tablet in Part B.
Trial: NCT02876003
Drug: G-202
RxNorm normalized name: krill/om-3/dha/epa/phospho/ast 500 mg-86 mg-25 mg-40 mg-202 mg-101 mcg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
Trial: NCT00927550
Drug: usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to the control arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Patients allocated to the control arm will not be allowed to receive lithium. Any other pharmacological treatment will be allowed.
Trial: NCT02417064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
Trial: NCT01574014
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 x 20 mg Hydrocortisone (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
Trial: NCT01574014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
Trial: NCT02453802
Drug: 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary total knee replacement with intravenous normal saline (20 ml) administration before deflation of the tourniquet
Trial: NCT02453802
Drug: 0.9% Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 160 ml normal saline application after closure of joint capsule.
Trial: NCT02918318
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
Trial: NCT03345342
Drug: PP3M 350 mg eq.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intramuscular injection of PP3M 350 mg eq.
Trial: NCT02437162
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1 and at Week 24 in Group 2 and Group 3.
Trial: NCT03981744
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive IV dosing of placebo at Week 24 in Group 1 and at Week 0 in Group 2.
Trial: NCT03981744
Drug: Placebo SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SC dosing of placebo at Weeks 8,16 and 24.
Trial: NCT01240954
Drug: OSIRIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSIRIS current practice
Trial: NCT03185819
Drug: Intranasal Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo as intranasal dose to match intranasal esketamine.
Trial: NCT02108418
Drug: TG-2349 as a new capsule formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose under fed condition
Trial: NCT01355471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: applied topically once daily
Trial: NCT04338321
Drug: SSRI/SNRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will continue to take SSRI/SNRI that is approved for use in depression in their country of participation; off-label use of any SSRI/SNRI is not permitted. The continuing SSRI/SNRI dosage may be optimized throughout the study, at the investigator's discretion and based on the SmPC (or local equivalent, if applicable).
Trial: NCT03246399
Drug: SM04690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suspension formulation of SM04690, delivered via intradiscal injection (single injection)
Trial: NCT02438787
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1.
Trial: NCT02130271
Drug: Radioactive dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The radioactive dye \[11C\]PBR28 will be administered through an intravenous line (IV).
Trial: NCT03375203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered once daily based upon dosing group.
Trial: NCT03375203
Drug: JNJ-42847922, 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42847922 will be administered as 5 mg (2\*2.5 mg capsule) oral capsules once daily.
Trial: NCT03375203
Drug: JNJ-42847922, 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42847922 will be administered as 10 mg oral capsule once daily.
Trial: NCT03375203
Drug: JNJ-42847922, 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42847922 will be administered as 20 mg oral capsule once daily.
Trial: NCT03277105
Drug: Dara SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
Trial: NCT03277105
Drug: Dara IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Dara IV 16 mg/kg once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
Trial: NCT03973047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule
Trial: NCT03321526
Drug: Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive SNRI antidepressant (such as duloxetine, milnacipran, levomilnacipran, venlafaxine, desvenlafaxine) as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
Trial: NCT00003511
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Multiple Myeloma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT03097133
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
Trial: NCT00302146
Drug: 15-0 H20
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02872818
Drug: 17β estradiol hemihydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg/kg/day for 20 days
Trial: NCT04688320
Drug: Recombinant nonimmunogenic staphylokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds
Trial: NCT00787813
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03666715
Drug: Oral Antipsychotics (OAPs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No study treatment will be administered as a part of this study. Participants will receive OAPs (such as olanzapine, risperidone, paliperidone, aripiprazole or quetiapine) as per their usual clinical practice.
Trial: NCT03429595
Drug: ATx201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATx201 GEL
Trial: NCT01184859
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo melt tablet for sublingual administration
Trial: NCT03098797
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily subcutaneous injection for 12 weeks
Trial: NCT02203526
Drug: TEDDI
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 21 days for cycles 2-6 (Arm 1-A); given every 21 days for cycles 1-6 (Arms 1-B, 2, 3 and 4)
Trial: NCT02203526
Drug: TEDD
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [LOCKE TEDDY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temozolomide, etoposide, doxil, dexamthasone, (TEDD) given on first cycle (Arm 1-A)
Trial: NCT02203526
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate on days 1 and day 5 of cycles 2-6 (Arm 4)
Trial: NCT03927677
Drug: Xanthine Oxidase Inhibitor
RxNorm normalized name: Xanthine oxidase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC350189 200mg qd
Trial: NCT02489266
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days.
Trial: NCT03614221
Drug: Lindioil ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each gram contains 200µg of indirubin. Apply 0.5 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
Trial: NCT03614221
Drug: Protopic ointment 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each gram contains (w/w) 0.1% of tacrolimus. Apply 0.1 g of ointment per 10 cm x 10 cm of affected skin areas twice daily for 6 weeks.
Trial: NCT04224493
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage 2:~Placebo administered orally twice daily in continuous 28-day cycles. Placebo will be administered as monotherapy twice daily dose for up to 2 years after the initial 12 months of combination therapy.
Trial: NCT03067610
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion
Trial: NCT02956122
Drug: methylprednisolone or equivalent steroid
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.
Trial: NCT00049335
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1,000 mg/m\^2/dose (2,000 mg/m\^2/day) BID, PO, on Days 1-14 of 21 day cycle
Trial: NCT03585556
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients
Trial: NCT04119024
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02170090
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1250mg/m2
Trial: NCT02137395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline administration intravenously
Trial: NCT03876002
Drug: [18F]PBR06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will undergo PET imaging using 1 single intravenous (IV) injection of \[18F\]PBR06, a PET radioligand for evaluation of microglial activation in the brain. PBR06 will be injected intravenously as a bolus at a dose of no more than 5.5mCi (millicurie).
Trial: NCT03449134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive dose-matched placebo tablets orally BID during the 12-week main study period and during the 40-week extension period.
Trial: NCT01997489
Drug: Enzyme replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observational study of current treatment and with no comparative groups
Trial: NCT00449436
Drug: Non-nucleoside reverse transcriptase inhibitor
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-nucleoside reverse transcriptase inhibitor
Trial: NCT00449436
Drug: Boosted Protease Inhibitor
RxNorm normalized name: Protease inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boosted Protease Inhibitor
Trial: NCT03151486
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo in all cohorts.
Trial: NCT03412877
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
Trial: NCT03412877
Drug: Pembrolizumab (KEYTRUDA(R))
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 2: Pembrolizumab 2 mg/kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
Trial: NCT01165359
Drug: ITX 5061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Part A of the study: 150 mg of ITX 5061, once a day for 3 days; 75 mg of ITX 5061, once a day for 3 days; or 25 mg of ITX 5061, once a day for 3 days.~For Part B of the study: 150 mg of ITX 5061, once a day for 14 days; 75 mg of ITX 5061, once a day for 14 days; or 25 mg of ITX 5061, once a day for 14 days.~For Part C of the study: 150 mg of ITX 5061, once a day for 28 days; 75 mg of ITX 5061, once a day for 28 days; or 25 mg of ITX 5061, once a day for 28 days.
Trial: NCT01165359
Drug: Placebo ITX 5061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For Part A of the study: placebo, once a day for 3 days.~For Part B of the study: placebo, once a day for 14 days.~For Part C of the study: placebo, once a day for 28 days.
Trial: NCT00555997
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0mg Placebo per day. Dose increases and dose decreases may occur, but patient will remain at 0mg placebo
Trial: NCT00130910
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole Placebo 400mg x 3 first dose observed
Trial: NCT00668330
Drug: Ibandronate+alfacalcidol+calcium
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium
Trial: NCT00668330
Drug: placebo ibandronate+alfacalcidol+calcium
RxNorm normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium
Trial: NCT02533349
Drug: Motilitone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg, 1 tablet, 3 times a day
Trial: NCT02533349
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg, 1 tablet, 3 times a day
Trial: NCT02151630
Drug: Pyruvic acid
RxNorm normalized name: Pyruvic acid
DrugBank: Pyruvic acid (DB00119)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00460564
Drug: GSK1358820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: botulinum toxin type A
Trial: NCT00460564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01245803
Drug: placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill is given 18-24hr and 4-6hr before PCI as control
Trial: NCT00018057
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomized assignment.
Trial: NCT02218489
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain loteprednol etabonate. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.
Trial: NCT03781713
Drug: Drug interaction risk D or X
RxNorm normalized name: alpha-D-galactosidase enzyme Oral Capsule [Gas-X Prevention]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention in the therapeutic plan in order to avoid adverse drug reactions.
Trial: NCT03781713
Drug: Antimicrobial stewardship
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimization of anticrobial therapy based on Gram stain, MALDI TOF, MIC and antimicrobial susceptibility
Trial: NCT04252287
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo capsules orally once daily.
Trial: NCT02396537
Drug: 0.9% Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intranasally prior to Midazolam administration.
Trial: NCT00214032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo 3 capsules daily
Trial: NCT03153111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated tablet (identical to the macitentan tablet); oral use
Trial: NCT03891524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo matching to JNJ-70033093, orally.
Trial: NCT02571283
Drug: Cocktail
RxNorm normalized name: Cocktail
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a single dose injection.
Trial: NCT01427192
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet (Mannitol) similar to acetazolamide
Trial: NCT00003423
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003423
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003423
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03067103
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 2mL of saline solution in peritonsillar fossa prior to surgery
Trial: NCT02254096
Drug: BIRT 1696 BS
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02254096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00670696
Drug: Rapydan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anaesthetic plaster
Trial: NCT04651556
Drug: paracetamol & ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: parenteral analgesics
Trial: NCT03384654
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participant will receive doxorubicin 60 mg/m\^2 in cohort 2.
Trial: NCT02046798
Drug: ASP3652
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02959177
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03384654
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participant will receive cyclophosphamide 1 gram per meter square (g/m\^2) once in cohort 2.
Trial: NCT03384654
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participant will receive methotrexate 5 g/m\^2 intravenously (IV) in cohort 2.
Trial: NCT00615173
Drug: cyclophosphamide or azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction phase: CTX 0.75g/m2 monthly Maintenance phase: AZA 2mg/kg/d.
Trial: NCT01163747
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A stable dose of between 7.5 and 25 mg/week, oral or parenteral.